Preclinical Models for Bladder Cancer Research

Zhu, Shaoming; Zhu, Zheng; Hong, Ai; Sonpavde, Guru; Pan, Chong Xian

doi:10.1016/j.hoc.2021.02.007

Cited by 13 publications

(11 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BCa research using a metabolomics-based approach has been pursued through the use of three main categories of samples, namely human fluids, in vitro cell lines and ex vivo tissues [ 48 , 49 ]. Each type of sample has its own unique features, advantages and disadvantages.…”

Section: Resultsmentioning

confidence: 99%

“…In the case of cell lines, they have been widely used in cancer research as a result of their capability to provide an unlimited self-replicating source of biological material. Additionally, they can provide an alternative to animal testing, and their characteristics are available on online databases, providing a better insight into the genetic profile and the alterations associated with each BCa molecular subtype [ 49 , 52 ]. On the downside, the extrapolation of in vitro to in vivo model systems is still a challenging concern in science research [ 53 ].…”

Section: Resultsmentioning

confidence: 99%

“…On the downside, the extrapolation of in vitro to in vivo model systems is still a challenging concern in science research [ 53 ]. Another drawback related to the use of in vitro cell lines is the fact that, when the culture lasts for a long period of time, they may be prone to the acquisition of epigenetic and genetic alterations [ 49 ]. Lastly, ex vivo bladder tissue samples imply a more direct study approach, providing information closely related to the tumor and its microenvironment; however, it is also a more invasive approach requiring certain expertise and special equipment, as well as careful, attentive and difficult sample preparation due to the sample heterogeneity [ 48 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Pereira,

Domingues,

Vitorino

et al. 2024

IJMS

View full text Add to dashboard Cite

Bladder cancer (BCa) research relying on Omics approaches has increased over the last few decades, improving the understanding of BCa pathology and contributing to a better molecular classification of BCa subtypes. To gain further insight into the molecular profile underlying the development of BCa, a systematic literature search was performed in PubMed until November 2023, following the PRISMA guidelines. This search enabled the identification of 25 experimental studies using mass spectrometry or nuclear magnetic resonance-based approaches to characterize the metabolite signature associated with BCa. A total of 1562 metabolites were identified to be altered by BCa in different types of samples. Urine samples displayed a higher likelihood of containing metabolites that are also present in bladder tumor tissue and cell line cultures. The data from these comparisons suggest that increased concentrations of L-isoleucine, L-carnitine, oleamide, palmitamide, arachidonic acid and glycoursodeoxycholic acid and decreased content of deoxycytidine, 5-aminolevulinic acid and pantothenic acid should be considered components of a BCa metabolome signature. Overall, molecular profiling of biological samples by metabolomics is a promising approach to identifying potential biomarkers for early diagnosis of different BCa subtypes. However, future studies are needed to understand its biological significance in the context of BCa and to validate its clinical application.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Pereira,

Domingues,

Vitorino

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…The cells are cultured in a humidified incubator at 37 °C and an atmosphere containing 5 % CO2. Passage culture should be performed when the cell growth reaches 80 %∼90 % [40] , [41] , [42] .…”

Section: Methodsmentioning

confidence: 99%

MAPKAP1 orchestrates macrophage polarization and lipid metabolism in fatty liver-enhanced colorectal cancer

Huang,

Yu,

Cui

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…The preclinical models of BCa include in vitro 2D models, such as cell lines from human, mouse, rat, dog, and conditionally reprogrammed cell cultures, in vitro 3D models, such as organoids and three-dimensional (3D) printing, in vivo models, such as carcinogen (such as BBN, amines, anthracenes, formamide FANFT)-induced model, genetically engineered mouse models, patient-derived xenograft models, and humanized models. However, the efficacy of ALT-803 has only been revealed in the BBN-induced rat and mouse models ( 41 ).…”

Section: Future Perspectivesmentioning

confidence: 99%

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

et al. 2022

View full text Add to dashboard Cite

Bladder cancer (BCa) is one of the most common malignant tumors that cause death. Approximately 75%–85% of BCa develop into non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Guérin (BCG) is the gold standard for avoiding cystectomy in the treatment of NMIBC. Unfortunately, up to 30% of patients do not respond to BCG treatment, and up to 70% of BCG responders relapse. The United States Food and Drug Administration (FDA) approved valrubicin (1998) and pembrolizumab (2020) for the treatment of BCG-unresponsive (BCGu) NMBIC. However, the complete remission rate for valrubicin and pembrolizumab was only 16% and 40.6%, respectively. ALT-803 (N-803) is an IL-15 superagonist and reduces tumor burden by promoting the proliferation and activation of NK cells and CD8+ T cells. The FDA received (23 May 2022) and accepted to review (28 July 2022) the marketing submission of ALT-803 plus BCG for the treatment of BCGu NMIBC. However, the FDA previously rejected the application for oportuzumab monatox (OM) due to a lack of data comparing it with pembrolizumab on August 20, 2021. Interestingly, the clinical efficacy and safety of ALT-803 were higher than that of pembrolizumab and OM, suggesting that ALT-803 may be approved by FDA. This review aims to further knowledge of the preclinical and clinical evidence of ALT-803 in the treatment of NMIBC and discuss its translational potential.

show abstract

Preclinical Models for Bladder Cancer Research

Cited by 13 publications

References 99 publications

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

MAPKAP1 orchestrates macrophage polarization and lipid metabolism in fatty liver-enhanced colorectal cancer

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

Contact Info

Product

Resources

About